We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation.
- Authors
Audard, Vincent; Kamar, Nassim; Sahali, Dil; Cardeau-Desangles, Isabelle; Homs, Sébastien; Remy, Philippe; Aouizerate, Jessie; Matignon, Marie; Rostaing, Lionel; Lang, Philippe; Grimbert, Philippe
- Abstract
Preventive treatment of focal and segmental glomerulosclerosis (FSGS) allograft recurrence in high risk recipients having a prior history of graft loss caused by FSGS recurrence is still a challenging question. We retrospectively identified four patients who underwent a second renal transplantation because of recurrent FSGS and who received Rituximab therapy as a prophylactic treatment. Loss of their first allograft was directly related to an early (<3 months) recurrence of FSGS that was either resistant to plasmapheresis therapy in two cases or had escaped to this therapeutic management in the two others. After the second renal transplantation, all patients were free of FSGS recurrence during follow-ups that were between 12 and 54 months long. These preliminary results demonstrate for the first time that Rituximab therapy may constitute an attractive prophylactic option for patients being considered for a second renal transplantation because of recurrent FSGS in their first graft.
- Publication
Transplant international : official journal of the European Society for Organ Transplantation, 2012, Vol 25, Issue 5, pe62
- ISSN
1432-2277
- Publication type
Journal Article
- DOI
10.1111/j.1432-2277.2012.01462.x